Bausch + Lomb CorpNYSE:BLCOView on Canadian Exchange
- LAST PRICE15.0900
- TODAY'S CHANGE (%)0.2200 (1.4795%)
- Bid / Lots14.8000/ 1
- Ask / Lots15.4300/ 1
- Open / Previous Close14.6900 / 14.8700
- Day Range
- 52 Week Range
- Volume133,546
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BLCO |
|---|---|---|
| 09:32 ET | 2239 | 14.755 |
| 09:43 ET | 1650 | 14.71 |
| 09:45 ET | 100 | 14.775 |
| 09:48 ET | 604 | 14.88 |
| 09:52 ET | 10100 | 14.855 |
| 10:01 ET | 1119 | 14.82 |
| 10:03 ET | 1900 | 14.82 |
| 10:06 ET | 1451 | 14.87 |
| 10:08 ET | 200 | 14.905 |
| 10:10 ET | 632 | 14.91 |
| 10:12 ET | 2056 | 14.92 |
| 10:14 ET | 100 | 14.92 |
| 10:15 ET | 100 | 14.92 |
| 10:21 ET | 200 | 14.96 |
| 10:24 ET | 400 | 14.95 |
| 10:28 ET | 200 | 14.96 |
| 10:32 ET | 627 | 14.95 |
| 10:33 ET | 100 | 14.95 |
| 10:46 ET | 100 | 14.955 |
| 10:48 ET | 100 | 14.95 |
| 10:51 ET | 100 | 14.935 |
| 10:55 ET | 600 | 14.95 |
| 11:02 ET | 100 | 14.96 |
| 11:06 ET | 124 | 14.9645 |
| 11:11 ET | 600 | 15.02 |
| 11:15 ET | 1263 | 15.02 |
| 11:18 ET | 3188 | 15.01 |
| 11:27 ET | 200 | 14.995 |
| 11:36 ET | 300 | 14.995 |
| 11:42 ET | 200 | 14.97 |
| 11:44 ET | 100 | 14.99 |
| 11:49 ET | 100 | 14.97 |
| 11:56 ET | 1467 | 15.01 |
| 11:58 ET | 301 | 15.015 |
| 12:00 ET | 395 | 15.04 |
| 12:03 ET | 900 | 15.02 |
| 12:12 ET | 200 | 15.01 |
| 12:14 ET | 136 | 15.02 |
| 12:16 ET | 400 | 15.025 |
| 12:18 ET | 100 | 15.03 |
| 12:23 ET | 100 | 15.02 |
| 12:34 ET | 714 | 15 |
| 12:38 ET | 100 | 15.01 |
| 12:39 ET | 208 | 15.01 |
| 12:41 ET | 435 | 14.995 |
| 12:50 ET | 100 | 14.99 |
| 12:52 ET | 164 | 14.99 |
| 12:54 ET | 100 | 15 |
| 12:56 ET | 200 | 15 |
| 12:57 ET | 410 | 15.01 |
| 12:59 ET | 100 | 15.04 |
| 01:10 ET | 100 | 15.0301 |
| 01:15 ET | 150 | 15.03 |
| 01:17 ET | 1892 | 15.03 |
| 01:19 ET | 307 | 15.02 |
| 01:21 ET | 100 | 15.02 |
| 01:24 ET | 500 | 15 |
| 01:26 ET | 400 | 15 |
| 01:28 ET | 100 | 15 |
| 01:32 ET | 505 | 15.01 |
| 01:37 ET | 100 | 15.005 |
| 01:39 ET | 910 | 15.02 |
| 01:42 ET | 200 | 15 |
| 01:44 ET | 100 | 15.005 |
| 01:46 ET | 100 | 15.01 |
| 01:48 ET | 200 | 15.01 |
| 01:57 ET | 200 | 15.01 |
| 02:02 ET | 1238 | 14.99 |
| 02:06 ET | 200 | 15 |
| 02:08 ET | 200 | 15 |
| 02:11 ET | 194 | 15.014 |
| 02:18 ET | 100 | 15.001 |
| 02:22 ET | 100 | 15 |
| 02:24 ET | 3481 | 15.06 |
| 02:26 ET | 300 | 15.07 |
| 02:31 ET | 300 | 15.09 |
| 02:33 ET | 200 | 15.09 |
| 02:36 ET | 335 | 15.06 |
| 02:38 ET | 701 | 15.05 |
| 02:40 ET | 100 | 15.05 |
| 02:45 ET | 1020 | 15.07 |
| 02:51 ET | 100 | 15.09 |
| 02:54 ET | 400 | 15.08 |
| 02:56 ET | 453 | 15.08 |
| 02:58 ET | 463 | 15.07 |
| 03:03 ET | 7185 | 15.09 |
| 03:05 ET | 900 | 15.06 |
| 03:12 ET | 100 | 15.05 |
| 03:14 ET | 100 | 15.04 |
| 03:18 ET | 100 | 15.04 |
| 03:30 ET | 850 | 15.05 |
| 03:34 ET | 100 | 15.04 |
| 03:36 ET | 100 | 15.05 |
| 03:38 ET | 949 | 15.045 |
| 03:39 ET | 100 | 15.03 |
| 03:41 ET | 750 | 15.045 |
| 03:43 ET | 100 | 15.07 |
| 03:45 ET | 700 | 15.02 |
| 03:48 ET | 550 | 15.04 |
| 03:50 ET | 1259 | 15.02 |
| 03:52 ET | 100 | 15.045 |
| 03:54 ET | 100 | 15.0301 |
| 03:56 ET | 1996 | 15.08 |
| 03:57 ET | 3364 | 15.1 |
| 03:59 ET | 23185 | 15.09 |
Jun 10, 2024
Bausch + Lomb INFUSE(R) for Astigmatism Silicone Hydrogel Daily Disposable Contact Lenses Introduced in the United States, from 7:00AM ET on Monday Jun 10, 2024 by Dow Jones
7:00AM ET on Monday Jun 10, 2024 by Dow Jones
Jun 3, 2024
Bausch + Lomb Launches Blink(TM) NutriTears(R) Clinically Proven Nutritional Supplement for Dry Eyes in the United States, from 7:00AM ET on Monday Jun 03, 2024 by Dow Jones
7:00AM ET on Monday Jun 03, 2024 by Dow Jones
May 29, 2024
Bausch + Lomb Announces 2024 Annual Meeting of Shareholder Results, from 4:30PM ET on Wednesday May 29, 2024 by Dow Jones
4:30PM ET on Wednesday May 29, 2024 by Dow Jones
May 28, 2024
Bausch + Lomb Announces Presentation of New Scientific Data and Evaluations Featuring Consumer, Vision Care and Pharmaceutical Products at Optometry's Meeting(R), from 9:00AM ET on Tuesday May 28, 2024 by Dow Jones
9:00AM ET on Tuesday May 28, 2024 by Dow JonesBausch + Lomb Receives Health Canada Approval for enVista(R) Envy(TM)* Full Visual Range Intraocular Lens, from 6:59AM ET on Tuesday May 28, 2024 by Dow Jones
6:59AM ET on Tuesday May 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Bausch + Lomb Corp | 5.2B | -15.7x | --- |
DENTSPLY SIRONA Inc | 5.5B | -58.4x | --- |
Lantheus Holdings Inc | 5.6B | 12.1x | +35.30% |
Merit Medical Systems Inc | 4.8B | 46.9x | +14.05% |
Stevanato Group SpA | 5.5B | 32.2x | --- |
Haemonetics Corp | 4.4B | 37.0x | +17.09% |
Company Information
Bausch + Lomb Corporation is an eye health company. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. The Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
Contact Information
- Headquarters
- 520 Applewood CrescentVAUGHAN, ON, Canada L4K 4B4
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Brenton Saunders
- Chief Financial Officer, Executive Vice President
- Sam Eldessouky
- President of Ophthalmic Pharmaceuticals
- Andrew Stewart
- Executive Vice President, Chief Legal Officer
- A. Robert Bailey
- Executive Vice President - Research & Development, Chief Medical Officer
- Yehia Hashad
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.2B |
|---|---|
Revenue (TTM) | $4.3B |
Shares Outstanding | 351.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.96 |
Book Value | $19.52 |
P/E Ratio | -15.7x |
Price/Sales (TTM) | 1.2 |
Price/Cash Flow (TTM) | 67.0x |
Operating Margin | 3.20% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
